Tozorakimab-placebo
Sponsors
AstraZeneca AB, Astrazeneca AB
Conditions
AsthmaChronic Obstructive Pulmonary Disease (COPD)Severe viral lung infections
Phase 2
Phase 3
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)
Active, not recruitingCTIS2023-505543-39-00
Start: 2024-02-12Target: 480Updated: 2026-01-26
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
RecruitingCTIS2023-507031-38-00
Start: 2023-01-09Target: 828Updated: 2026-01-09
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
Active, not recruitingCTIS2023-503571-19-00
Start: 2022-01-20Target: 479Updated: 2025-11-13
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)
Active, not recruitingCTIS2023-503572-24-00
Start: 2022-03-02Target: 350Updated: 2025-10-30